Acta Scientific Microbiology (ISSN: 2581-3226)

Editorial Volume 5 Issue 2

COVID-19 Vaccine Efficacy on Omicron Variant

Attapon Cheepsattayakorn1,2*, Ruangrong Cheepsattayakorn3 and Porntep Siriwanarangsun1

1Faculty of Medicine, Western University, Pathumtani Province, Thailand
210th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
3Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: December 22, 2021; Published: January 01, 2022

B.1.1.529 or Omicron variant, a variant of concern, designated by the World Health Organization (WHO) on November 26, 2021, on the suggestion of the WHO’s Technical Advisory Group on Virus Evolution (TAG-VE) [1]. Whether Omicron variant is more transmissible or causes more severe COVID-19 is not yet clear compared to other SARS-CoV-2 (COVID-19) variants, including Delta variant [1]. Several epidemiological studies are ongoing in South Africa, first country of Omicron variant identification with rising of number of SARS-CoV-2 (COVID-19)-positive persons [1]. Currently, no information on different Omicron-related symptoms is available, compared to other COVID-19 variants [1]. Increased risk of Omicron-variant reinfection could easily occur in individuals with previous COVID-19 infection [1]. Reverse-transcriptase-polymerase-chain reaction (RT-PCR) continuously is the method of Omicron variant detection [1]. A recent study in England demonstrated that the vaccine efficacy (VE) after 15 weeks of two doses of BNT162b2 (Pfizer) vaccine was around 88.0 %, whereas there was no effect against Omicron variant after two doses of ChAdOx1 (AstraZeneca) vaccine [2]. Effectiveness of current treatments currently underway [1].


  1. World Health Organization. “Update on Omicron” (2021).
  2. Andrews N., et al. “Posted on December 14, 2021. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern”. medRxiv (2021).


Citation: Attapon Cheepsattayakorn., et al. “COVID-19 Vaccine Efficacy on Omicron Variant”. Acta Scientific Microbiology 5.2 (2022): 01.


Copyright: © 2022 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate33%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US